Blend Gets $16M in Series B; Brewing Platinum Nano-Drug
By Randy Osborne
Wednesday, December 19, 2012
With a new CEO and $16 million in Series B money, combination-drug developer Blend Therapeutics Inc. is putting oomph behind a platinum-based therapy a new chemical entity unto itself to be made with the company's nanoparticle technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.